
Aravive ARAV
Quarterly report 2023-Q3
added 11-09-2023
Aravive Operating Expenses 2011-2026 | ARAV
Annual Operating Expenses Aravive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 80 M | 48.1 M | 30.7 M | 26.5 M | 38.5 M | 124 M | 96.3 M | 82.5 M | 46.1 M | 19.3 M | 12.9 M | 8.16 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 124 M | 8.16 M | 51.1 M |
Quarterly Operating Expenses Aravive
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.7 M | 13.9 M | 19.4 M | - | 21.5 M | 21 M | 16.1 M | - | 14 M | 11.2 M | 8.26 M | - | 10.7 M | 5.72 M | 10.3 M | - | 7 M | 6.93 M | 7.44 M | - | 6.22 M | 9.44 M | 8.52 M | 8.89 M | 49.7 M | 36.2 M | 29.7 M | 22.5 M | 27.4 M | 22.3 M | 24.1 M | 20.2 M | 20.5 M | 19.5 M | 22.3 M | 15.9 M | 14.1 M | 8.5 M | 7.58 M | 5.86 M | 5.26 M | 3.98 M | 4.18 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 49.7 M | 3.98 M | 15.2 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
Aligos Therapeutics
ALGS
|
90.2 M | $ 8.7 | 8.82 % | $ 86 M | ||
|
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.63 | -2.42 % | $ 8.73 B | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | ||
|
Anavex Life Sciences Corp.
AVXL
|
51.4 M | $ 3.06 | 3.73 % | $ 261 M | ||
|
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
BioNTech SE
BNTX
|
512 M | $ 97.5 | 2.09 % | $ 27.2 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 20.5 | 0.64 % | $ 958 M | ||
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
173 M | $ 1.43 | 1.79 % | $ 368 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | ||
|
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 2.96 | 1.37 % | $ 4.87 M | ||
|
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.16 | 1.84 % | $ 445 M | ||
|
Arcutis Biotherapeutics
ARQT
|
137 M | $ 24.22 | 0.04 % | $ 3.08 B | ||
|
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
58.1 M | $ 32.51 | 0.84 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.51 | 1.01 % | $ 402 M | ||
|
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | ||
|
Cidara Therapeutics
CDTX
|
177 M | - | - | $ 1.41 B | ||
|
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
53.7 M | $ 2.61 | 2.35 % | $ 16.4 M | ||
|
InflaRx N.V.
IFRX
|
52.4 M | $ 1.07 | 7.0 % | $ 152 M | ||
|
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | ||
|
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
Akari Therapeutics, Plc
AKTX
|
17.3 M | $ 3.99 | 4.2 % | $ 269 B | ||
|
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | ||
|
Baudax Bio
BXRX
|
54.6 M | - | 0.59 % | $ 63 K | ||
|
Cabaletta Bio
CABA
|
172 M | $ 3.25 | 3.83 % | $ 327 M | ||
|
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B |